Ascendis Pharma A/S Announces Participation at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
November 25, 2020 07:05 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product...
Ascendis Pharma A/S to Host Virtual Oncology R&D Day on Friday, November 20
November 11, 2020 17:30 ET
|
Ascendis Pharma
– Event will provide an overview of how Ascendis is applying its TransCon™ technology platform and its unique algorithm for product innovation to the therapeutic area of oncology – COPENHAGEN,...
Ascendis Pharma A/S Reports Third Quarter 2020 Financial Results
November 11, 2020 16:01 ET
|
Ascendis Pharma
– European Medicines Agency (EMA) validated the Marketing Authorisation Application (MAA) for TransConTM hGH (lonapegsomatropin) in pediatric growth hormone deficiency (GHD) – – Submitted...
Ascendis Pharma A/S Appoints Dr. Mark A. Bach as Senior Vice President of Clinical Development and Medical Affairs for Endocrinology Rare Diseases
November 03, 2020 07:05 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
Ascendis Pharma A/S Announces Third Quarter 2020 Financial Results and Business Update Conference Call on November 11
November 02, 2020 16:05 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
Ascendis Pharma A/S Receives Orphan Designation for TransCon™ PTH for Treatment of Hypoparathyroidism in Europe
October 23, 2020 08:05 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical...
Ascendis Pharma A/S Announces Presentations for its Endocrinology Rare Disease Clinical Programs at Upcoming Medical Conferences
October 21, 2020 17:51 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
Ascendis Pharma A/S Announces Preliminary Six-Month Data from Open-Label Extension of Phase 2 PaTH Forward Trial and Files IND Amendment to Initiate Phase 3 PaTHway Trial of TransCon™ PTH in Adult Hypoparathyroidism
September 28, 2020 19:00 ET
|
Ascendis Pharma
- Six-month data from PaTH Forward open-label extension support potential use of TransCon PTH as a hormone replacement therapy for adult hypoparathyroidism –- Conference call Tuesday, September...
Ascendis Pharma A/S Announces Filing of the Clinical Trial Notification for Phase 3 Clinical Trial of TransCon™ hGH for Pediatric Growth Hormone Deficiency in Japan
September 23, 2020 16:05 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical...
Ascendis Pharma A/S Announces Support for Children’s Growth Awareness Week and Day 2020
September 15, 2020 17:45 ET
|
Ascendis Pharma
– Introduces #Together4Growth to increase awareness of children’s growth disorders, including a four-question Growth Quiz to help parents identify signs and symptoms – – Public encouraged to...